Charles Casamento

Charles J.
Casamento founded Indevus Pharmaceuticals, Inc. in 1989, where he worked as President & Chief Executive Officer from 1989 to 1993 and Questcor Pharmaceuticals, Inc. in 1999, where he worked as Chairman, President & Chief Executive Officer from 1999 to 2004.
Mr. Casamento also currently works at Relmada Therapeutics, Inc., as Chairman from 2017, GT Biopharma, Inc., as Independent Director from 2023, KineMed, Inc., as Director from 2013, Sage Healthcare Ltd., as Executive Director from 2014, Astex Pharmaceuticals, Inc., as Independent Director from 2002, The Sage Group LLC (Washington), as Executive Director & Principal from 2007, Eton Pharmaceuticals, Inc., as Independent Director from 2017, PaxMedica, Inc., as Director, and Fordham University, as Member-Science Council.
Mr. Casamento also formerly worked at RiboGene, Inc., as Chairman, President & Chief Executive Officer from 1993 to 1999, Osteologix, Inc., as President & Chief Executive Officer from 2004 to 2007, RespireRx Pharmaceuticals, Inc., as Chairman from 2012 to 2013, Catholic Medical Mission Board, Inc., as Vice Chairman, SuperGen, Inc., as Director from 2002 to 2011, VIVUS, Inc., as Independent Director from 2011 to 2013, International Stem Cell Corp., as Independent Director from 2011 to 2019, Mount Saint Michael Academy, Inc., as Director, GridAI Technologies Corp., as Independent Director from 2017 to 2024, PaxMedica, Inc., as Lead Independent Director from 2023 to 2025, Johnson & Johnson, as VP-Business Development & Strategic Planning, Genzyme Corp., as Senior VP-Pharmaceuticals & Biochemicals from 1985 to 1989, Sandoz, Inc., as VP-Business Development & Strategic Planning, Hoffmann-La Roche, Inc., as VP-Business Development & Strategic Planning, and American Hospital Supply Corp., as VP-Business Development & Strategic Planning from 1983 to 1985.
Mr. Casamento received his undergraduate degree in 1968 from Fordham University and Masters Business Admin degree in 1971 from Iona College.